Parenteral Drugs (India) Ltd

BSE: 524689 | NSE: PDPL | ISIN: INE904D01019 
Market Cap: [Rs.Cr.] 78.28 | Face Value: [Rs.] 10
Industry: Pharmaceuticals - Indian - Formulations

Company Profile

Parenteral Drugs (India) Ltd is an India-based pharmaceutical company. The company develops, manufactures, and markets a range of pharmaceutical products in India. Their products include solid and liquid orals, such as antibiotics and anti-bacterial, anti-ulcerant, analgesics/anti-inflammatory, multivitamins and minerals, anxiolyic , antiprotozoal, anticold, anthelmintic, anti-histaminic, muscle relaxant, cardiac, antidiabetic, cough syrup, appetite enhancer and injections. The company produces various therapeutic segments of In-Vitro (I V) Fluids, such as electrolytes, antibacterial, energy replenisher, irrigation solution, osmotic diuretic, dialysis solution. They also produce 400-milligram Ciprofloxacin infusion in 200 milliliter with 5% dextose. Apart from the single dose dispensers, the company has also launched multi-dose eye/ ear drops in plastic containers. The dispensers are made using the form-fill-seal technology. Parenteral Drugs (India) Ltd was incorporated in the year 1983 as a private limited company. In the year 1989, the company established their first unit to manufacture I V Fluids in Polypropylene containers with a capacity of 18 lakh bottles per annum. In March 1994, the company was converted into a public limited company. In September 1994, the company came out with a public issue at a premium of Rs 80, aggregating Rs 7.03 crore, to part-finance their Rs 8.97crore expansion. During the year 1994-95, the company set up a joint venture unit in Ukraine for manufacture of a wide range of pharmaceuticals. In addition, they set up a unit for the manufacture of I V Fluids at Jalandhar in Punjab. During the year 1997-98, the company purchased 100% equity of the Parenteral Drugs International Ltd and made it a wholly owned subsidiary of the company. They also purchased 50% equity in Parental Drugs (Punjab) Ltd. During the year 1999-2000, the company was awarded ISO 9002 Certification as a symbol of quality products. During the year 2003-04, the company installed Injections with the production capacity of 516 lakh numbers. During the year 2005-06, the company increased the production capacity of I V Fluid Transfusion by 45,000,000 Nos to 120,000,000 Nos. In addition, they set up a plant for manufacturing pharmaceutical products at Baddi in Himachal Pradesh. During the year 2006-07, the company increased the production capacity of Tablets/ Capsules by 1,125,000,000 Nos, Ampoules by 90,000,000 Nos and Injections 56,400,000 Nos. During the year 2007-08, they increased the production capacity of Large Volume by 30,000,000 Nos and Ampoules by 95,000,000 Nos. The company has decided to amalgamate two of their group companies, namely PFL Holdings Pvt Ltd and Goa Holdings (India) Pvt Ltd, into the company. As a result of this amalgamation, their respective subsidiaries, namely Punjab Formulations Ltd and Goa Formulations Ltd shall become the wholly owned subsidiaries of the company.

Futures & Options Quote
Future Data Not present
Key Information

Key Executives:

Manoharlal Gupta , Chairman

Vinod Kumar Gupta , Managing Director

Govind Das Garg , Whole-time Director

Satish Chandra Consul , Director


Company Head Office / Quarters:

340 Laxmi Plaza Laxmi Indl Est,
New Link Road Andheri (West),
Mumbai,
Maharashtra-400053
Phone : Maharashtra- / Maharashtra-
Fax : Maharashtra- / Maharashtra-
E-mail : pdpl@pdlindia.com
Web : http://www.pdindia.com

Registrars:


 
Fund Holding
Scheme Name No. of Shares
 
 
Better Investment Avenue

Check whether Taxed / Tax free investment avenue is better for you

  Taxed Avenue Tax-Free Avenue
Investment amount (Rs.)  
Tenure of Investment (years)  
Interest earned (% p.a)
Compounded every
Your tax bracket (%)